A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 65
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : ALLN
Long Form : N-acetyl-leucyl-leucyl-norleucinal
No. Year Title Co-occurring Abbreviation
2021 Loss-of-Function Piezo1 Mutations Display Altered Stability Driven by Ubiquitination and Proteasomal Degradation. ---
2018 The role and mechanism of chaperones Calnexin/Calreticulin in which ALLN selectively rescues the trafficking defective of HERG-A561V mutation. CNX, CRT, LQT, PROP
2018 VEGF-A selectively inhibits FLT1 ectodomain shedding independent of receptor activation and receptor endocytosis. Flt, KDR
2016 Dissociation of NSC606985 induces atypical ER-stress and cell death in prostate cancer cells. CRPC, Epo, PCa
2016 Inhibition of calpain on oxygen glucose deprivation-induced RGC-5 necroptosis. OGD, RGC-5, tAIF
2016 The Toxic Effect of ALLN on Primary Rat Retinal Neurons. LC3, LDH, MDC, PI
2016 [Overexpression of NHE1 suppresses ABCA1 protein expression via increasing calpain activity in RAW264.7 cells]. ABCA1, AdNHE1, NHE1
2013 Anti-malarial activity of new N-acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) derivatives against Plasmodium falciparum. TI
2012 Synthesis and evaluation of peptidyl alpha,beta-unsaturated carbonyl derivatives as anti-malarial calpain inhibitors. ---
10  2010 The production of 85 kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apoB gene occurs by ALLN-inhibitable protease cleavage during translocation. ---
11  2009 Antimalarial effect of N-acetyl-L-Leucyl-L-leucyl-L-norleucinal by the inhibition of Plasmodium falciparum Calpain. ---
12  2009 Reduced amyloidogenic processing of the amyloid beta-protein precursor by the small-molecule Differentiation Inducing Factor-1. AD, APP, DIF-1
13  2009 Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. DV, Hb, PMs
14  2008 An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. AMPK, eNOS, PI3K, VEGF
15  2008 Glutamate alteration of glutamic acid decarboxylase (GAD) in GABAergic neurons: the role of cysteine proteases. GAD, NMDAR
16  2008 Proteasome affects the expression of aryl hydrocarbon receptor-regulated proteins. 3-MC, AhR, EROD
17  2007 Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. ER, GO, MBs
18  2007 Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. COX-2, IkappaBalpha, MMP-9, RANKL, TNF, VEGF
19  2007 Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages. CE, HMDM, LDLR, nLDL, siRNA-LRP1, SREBPs
20  2006 Differential regulation of eotaxin-1/CCL11 and eotaxin-3/CCL26 production by the TNF-alpha and IL-4 stimulated human lung fibroblast. MAPK
21  2006 [Effect of ubiquitin-proteasome pathway on inflammatory reaction in intestine and its barrier function in rats with postburn sepsis]. DAO, ELISA, EMSA, LPS, NF-KappaB, PDTC, TBSA, TNF-alpha
22  2005 Octanoate reduces very low-density lipoprotein secretion by decreasing the synthesis of apolipoprotein B in primary cultures of chicken hepatocytes. apoB, BSA, TG, VLDL
23  2004 Calpain inhibitors improve myocardial dysfunction and inflammation induced by endotoxin in rats. ---
24  2004 Inhibition of apolipoprotein B secretion by taurocholate is controlled by the N-terminal end of the protein in rat hepatoma McArdle-RH7777 cells. apoB, BS, McA-RH7777, TC, TG
25  2004 Interleukin-8 production by THP-1 cells stimulated by Salmonella enterica serovar Typhimurium porins is mediated by AP-1, NF-kappaB and MAPK pathways. AP-1, IL-8, LPS, NF-kappaB, PTKs
26  2003 Amino acid sequences within the beta1 domain of human apolipoprotein B can mediate rapid intracellular degradation. apoB, FABPs
27  2003 I kappa B overexpression in cardiomyocytes prevents NF-kappa B translocation and provides cardioprotection in trauma. NF-kappaB, TNF-alpha
28  2003 The biological response of MCF7 breast cancer cells to proteosome inhibition or gamma-radiation is unrelated to the level of p53 induction. ---
29  2002 Green tea catechins decrease apolipoprotein B-100 secretion from HepG2 cells. apoB, EC, EGCG
30  2002 Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. apoB, CE, ER, MTP
31  2001 Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells. 4-HPR, dnFADD, dnFLICE, NAC
32  2001 Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. ERAD
33  2000 Pharmacologic interference with NF-kappaB activation attenuates central nervous system complications in experimental Pneumococcal meningitis. CSF
34  2000 Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. ADD-1, CEBPalpha, GPDH, PPARgamma, SREBP-1, TG
35  2000 The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase. ALLM, HMGR, MVA
36  1999 Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase. Evidence that substrate availability limits beta-amyloid peptide production. APP
37  1999 Dietary fish oils inhibit early events in the assembly of very low density lipoproteins and target apoB for degradation within the rough endoplasmic reticulum of hamster hepatocytes. apo
38  1999 Protein kinase C-dependent activation of NF-kappaB in enterocytes is independent of IkappaB degradation. IL, PMA
39  1998 Annexin VI-mediated loss of spectrin during coated pit budding is coupled to delivery of LDL to lysosomes. LDL
40  1998 Characterization of two Chinese hamster ovary cell lines expressing the COOH-terminal domains of sterol regulatory element-binding protein (SREBP)-1. CHO, ER, HMG-CoA, SREBP, SREBPs
41  1998 Lipopolysaccharide-induced NF-kappaB activation in human endothelial cells involves degradation of IkappaBalpha but not IkappaBbeta. HMA, HUVEC, LPS
42  1997 A two-site model for ApoB degradation in HepG2 cells. apoB, BFA, DTT, ER, OA
43  1997 Conformational changes in apolipoprotein B modulate intracellular assembly and degradation of ApoB-containing lipoprotein particles in HepG2 cells. ---
44  1997 Cytosolic degradation of T-cell receptor alpha chains by the proteasome. ER, TCR
45  1997 Intracellular assembly and degradation of apolipoprotein B-100-containing lipoproteins in digitonin-permeabilized HEP G2 cells. apoB-100
46  1997 N-acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-kappaB activation and prevents TNF and IL-6 synthesis in vivo. ---
47  1996 Blocking intracellular degradation of the erythropoietin and asialoglycoprotein receptors by calpain inhibitors does not result in the same increase in the levels of their membrane and secreted forms. ALLM, ASGPR, EpoR
48  1996 Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells. ---
49  1996 Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B. apoB
50  1995 Effect and cellular site of action of cysteine protease inhibitors on the cholesterol esterification pathway in macrophages and Chinese hamster ovary cells. ACAT, beta-VLDL, EST
51  1995 Heterologous expression of apolipoprotein B carboxyl-terminal truncates: a model for the study of lipoprotein biogenesis. apoB, ER
52  1995 Intracellular degradation of apolipoprotein B generates an N-terminal 70 kDa fragment in the endoplasmic reticulum. ER
53  1995 The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells. CDCA
54  1994 Microsomal triglyceride transfer protein, the abetalipoproteinemia gene product, mediates the secretion of apolipoprotein B-containing lipoproteins from heterologous cells. ABL, apo, MTP
55  1994 Regulated intracellular degradation of apolipoprotein B in semipermeable HepG2 cells. ---
56  1994 Sterol mediated regulation of SREBP-1a,1b,1c and SREBP-2 in cultured human cells. LDL, SREBPs
57  1994 The regulated degradation of a 3-hydroxy-3-methylglutaryl-coenzyme A reductase reporter construct occurs in the endoplasmic reticulum. HM-Gal, HMG-CoA
58  1993 Cellular detoxification of tripeptidyl aldehydes by an aldo-keto reductase. CHO, MDR
59  1993 In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal. ---
60  1993 Inhibition of apolipoprotein E degradation in a post-Golgi compartment by a cysteine protease inhibitor. APOE
61  1993 Proteolysis and lipid-facilitated translocation are distinct but competitive processes that regulate secretion of apolipoprotein B in Hep G2 cells. ---
62  1992 Peptide transport by the multidrug resistance pump. MDR
63  1992 Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in a nonhepatic cell line. apoB, CHO
64  1991 Inhibition of degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in vivo by cysteine protease inhibitors. ALLM, CHO, ER, HMG-CoA, LDL
65  1990 Cysteine proteinase inhibitors and ras gene products share the same biological activities including transforming activity toward NIH3T3 mouse fibroblasts and the differentiation-inducing activity toward PC12 rat pheochromocytoma cells. ALLM